Scilex Holding (SCLX) Total Non-Current Liabilities (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Total Non-Current Liabilities of $522.2 million for Q1 2026, up 84.79% year-over-year from $282.6 million in Q1 2025, and down 9.43% quarter-over-quarter from $576.6 million in Q4 2025.
Scilex Holding (SCLX) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Scilex Holding's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $522.2 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 84.79% year-over-year to $522.2 million; the TTM figure through Mar 2026 stood at $522.2 million (up 84.79% YoY), while the FY2025 annual figure was $576.6 million, up 102.59% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $522.2 million, down from $576.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $576.6 million in Q4 2025, with the low at $7.3 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $264.8 million (2025), against an average of $235.3 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities plunged 81.57% in 2022, then soared 2090.64% in 2023.
- Scilex Holding's Total Non-Current Liabilities stood at $49.1 million in 2022, then jumped by 234.55% to $164.1 million in 2023, then jumped by 73.4% to $284.6 million in 2024, then surged by 102.59% to $576.6 million in 2025, then slipped by 9.43% to $522.2 million in 2026.
- Business Quant data shows SCLX's Total Non-Current Liabilities at $522.2 million in Q1 2026, $576.6 million in Q4 2025, and $455.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.61 Bn | 630.85 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 470.09 Bn | 463.53 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 374.19 Bn | 367.05 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 302.72 Bn | 295.03 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.19 Bn | 252.29 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 236.77 Bn | 222.78 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 182.67 Bn | 179.49 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 159.54 Bn | 147.84 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 105.97 Bn | 101.81 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Scilex Holding | 38.94 Mn | -73.85 Mn | 3.97 Mn | 482.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 522.16 Mn |
| Dec 31, 2025 | 576.56 Mn |
| Sep 30, 2025 | 455.43 Mn |
| Jun 30, 2025 | 264.84 Mn |
| Mar 31, 2025 | 282.57 Mn |
| Dec 31, 2024 | 284.59 Mn |
| Sep 30, 2024 | 311.59 Mn |
| Jun 30, 2024 | 319.05 Mn |
| Mar 31, 2024 | 280.84 Mn |
| Dec 31, 2023 | 164.12 Mn |
| Sep 30, 2023 | 241.10 Mn |
| Jun 30, 2023 | 109.48 Mn |
| Mar 31, 2023 | 68.49 Mn |
| Dec 31, 2022 | 49.06 Mn |
| Sep 30, 2022 | 11.01 Mn |
| Jun 30, 2022 | 51.65 Mn |
| Mar 31, 2022 | 7.33 Mn |
| Dec 31, 2021 | 266.11 Mn |
| Sep 30, 2021 | 5.23 Mn |
| Jun 30, 2021 | 5.21 Mn |